Skip to main content

March 2016

From San Francisco Business Times, BiotechSF

Like the journey of a thousand miles, the path leading to an Alzheimer’s disease treatment begins with a single step: Getting people through the doors of hundreds of clinical trial sites.

Now a program based at the University of California, San Francisco, is teaming up with a global foundation to build out a registry of current and potential Alzheimer’s patients from which the right people can be quickly assigned to the right drug studies.

The Brain Health Registry is a matter of time and money, said Dr. Michael Weiner, director of the registry and a professor of radiology and biomedical engineering, medicine, psychiatry and neurology at UCSF. It could potentially accelerate clinical trials by cutting down on the time it takes to enroll study participants.

Read more